Revolution Medicines (NasdaqGS:RVMD) Update / Briefing September 10, 2025 05:00 PM ET Company ParticipantsRyan Asay - SVP & Corporate AffairsMark Goldsmith - CEO, President & ChairmanSteve Kelsey - President - Research & DevelopmentWei Lin - Chief Medical OfficerMorgan Lamberti - Equity Research AssociateEllie Merle - Executive Director - Biotech Equity ResearchConference Call ParticipantsJonathan Chang - Senior MD & Senior Research AnalystMichael Schmidt - Senior MD & Equity Research Analyst - Biotechnolog ...